Wrapping up a challenging 2023, Chinese pharma firms increasingly ventured into the US to initiate Phase III clinical trials to support future regulatory approvals from the US Food and Drug Administration for their new drug candidates.
Key Takeaways
-
In 2023, as the sole trial sponsor, Chinese firms initiated eight Phase III trial programs that included US sites, reversing a fall in the number to six in 2022 from 11 in 2021.
Last year, as the sole trial sponsor, companies from China commenced a total of eight Phase III programs that included...